Solid Biosciences (SLDB) Given a $6.00 Price Target by Citigroup Analysts

Citigroup set a $6.00 price objective on Solid Biosciences (NASDAQ:SLDB) in a report published on Thursday, TipRanks reports. The brokerage currently has a hold rating on the stock.

Several other research analysts have also issued reports on SLDB. Chardan Capital reissued a buy rating and issued a $15.00 target price on shares of Solid Biosciences in a research report on Thursday, February 7th. Leerink Swann lowered Solid Biosciences from an outperform rating to a market perform rating in a research report on Thursday, February 7th. Svb Leerink lowered Solid Biosciences from an outperform rating to a market perform rating in a research report on Friday, February 8th. Zacks Investment Research raised Solid Biosciences from a hold rating to a buy rating and set a $8.25 target price for the company in a research report on Wednesday, February 13th. Finally, ValuEngine raised Solid Biosciences from a hold rating to a buy rating in a research report on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and one has assigned a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $19.82.

Shares of NASDAQ:SLDB traded down $0.14 during trading on Thursday, hitting $6.04. The stock had a trading volume of 330,214 shares, compared to its average volume of 871,348. Solid Biosciences has a 12 month low of $5.23 and a 12 month high of $54.84. The firm has a market capitalization of $209.25 million, a P/E ratio of -2.68 and a beta of 1.68. The company has a debt-to-equity ratio of 0.07, a quick ratio of 10.31 and a current ratio of 6.99.

Solid Biosciences (NASDAQ:SLDB) last announced its earnings results on Monday, May 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.22). On average, equities analysts forecast that Solid Biosciences will post -2.53 EPS for the current fiscal year.

In related news, Director Juan Andrey Zarur sold 8,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $10.00, for a total value of $80,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Boxer Capital, Llc sold 450,000 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $9.88, for a total value of $4,446,000.00. The disclosure for this sale can be found here. Corporate insiders own 31.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in Solid Biosciences by 90.3% in the third quarter. Wells Fargo & Company MN now owns 8,241 shares of the company’s stock valued at $389,000 after acquiring an additional 3,911 shares during the period. Bank of New York Mellon Corp grew its position in Solid Biosciences by 31.0% during the third quarter. Bank of New York Mellon Corp now owns 41,778 shares of the company’s stock worth $1,971,000 after buying an additional 9,889 shares in the last quarter. BlackRock Inc. boosted its holdings in shares of Solid Biosciences by 30.6% in the 3rd quarter. BlackRock Inc. now owns 778,249 shares of the company’s stock worth $36,718,000 after purchasing an additional 182,315 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Solid Biosciences in the 3rd quarter worth about $424,000. Finally, Teachers Advisors LLC boosted its holdings in shares of Solid Biosciences by 14.3% in the 3rd quarter. Teachers Advisors LLC now owns 21,653 shares of the company’s stock worth $1,022,000 after purchasing an additional 2,710 shares in the last quarter. Institutional investors own 63.39% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.